Lupin

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to Watch today, Feb 17: Cochin Shipyard, JSW Infra, Lupin, Seamec

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Analyst at Kotak Sec bets on ICICI Bank, Lupin

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

Lupin rises post-Q3 analysts call, but brokerages flag FY27 earnings risk

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

Lupin settles US patent dispute with Astellas Pharma for $90 million

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Lupin signs exclusive India pact with Gan & Lee for fortnightly GLP-1 drug

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle

Lupin gets US FDA nod for its first biosimilar drug Pegfilgrastim

The product, a biosimilar to Amgen's popular drug Neulasta, will be manufactured at Lupin's biotech facility in Pune

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Lupin launches generic injection in US with 180-day exclusivity

Drug maker Lupin on Friday said it has launched a generic medication to treat schizophrenia in the US with 180 days of exclusivity. The company has launched Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, single-dose vials, with 180-day CGT exclusivity in the US, the Mumbai-based drug maker said in a statement. This follows the recent approval received from the US Food and Drug Administration (USFDA). This is the company's first product using proprietary technology from PrecisionSphere, the Long-acting Injectable (LAI) platform developed by its subsidiary Nanomi BV. Risperidone for extended-release injectable suspension is bioequivalent and therapeutically equivalent to the reference listed drug Risperdal Consta LAI. It is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults. As per IQVIA MA

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Stocks to Watch today, Nov 7: Bharti Airtel, LIC, Lupin, Bajaj Housing

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

Lupin Q2 PAT rises 73% on strong growth across key global markets

Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix

Stocks to watch today, Oct 13: HCLTech, Tata Capital, DMart, Axis Bank, HCC

Stocks to watch on October 13, 2025: Stocks like HCL Technologies, Just Dial, Anand Rathi Wealth, and Den Networks will remain in focus as they will release their quarterly earnings today.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Lupin shares jump 4% on new Florida manufacturing facility plan

Lupin said the project aims to boost medicine security, diversify supply chains, and reinforce its position as a global leader in respiratory therapies